body (Clone AC-150; Sigma, St. Louis, MO, USA) with a dilution of 1:5000 in blocking solution as previously described. The secondary antibody used for β -actin was HRP-conjugated goat polyclonal anti-mouse IgG (Transduction Laboratories, Lexington, KY, USA). The rest of the procedure was the same as for Cox 1. Figure 1 shows that both Western blots were able to detect one single band with the expected molecular weight. As we expected, there was no detection of Cox 1 signal on the β -actin blot, even after a longer exposure (data not shown). This result is because the HRP on the Cox 1 blot had already been inactivated by hydrogen peroxide in SuperSignal substrate and the duration of chemiluminescence produced by SuperSignal substrate was only 6-8 h. To further investigate the HRP inactivation rate and chemiluminescence duration, we then produced another Cox 1 blot. This one was exposed to an X-ray film for 5 min immediately, and at 1, 2 or 4 h after substrate incubation. We were not able to detect any signal at the 4 h time point (data not shown). This blot was then washed once with PBST for 10 min at room temperature and incubated with fresh substrate again for 5 min. We did not detect any signal even after overnight exposure (data not shown), which indicates that the amount of hydrogen peroxide in SuperSignal substrate is sufficient to inactivate HRP 4 h after incubation. The following morning, this blot was washed once in PBST for 10 min, and then the same procedure for Cox 1 detection was repeated. We failed to detect any Cox 1 signal even after overnight exposure (data not shown), indicating that normal washes in PBST are not sufficient to remove antibodies from an antigen-antibody complex.
For Western blotting analysis, the primary antibody is usually present at a much higher quantity than the target protein, as is the secondary antibody to primary antibody. Because the bound antibodies cannot be removed by normal washing, the antibodies directly reprobed for internal control will neither affect nor be affected by the detection of the primary target, even though the same secondary antibody is used. The direct reprobing method was also successfully used for detecting both βactin and other target proteins, such as the HA epitope (antibody generated in rat) and the ErbB 4 (antibody generated in rabbit) from cultured cell lines (data not shown).
In summary, the entire procedure of the direct reprobing method for internal control analysis omits the stripping and reblocking steps. By using this method, signal attenuation by high-stringency stripping does not occur. Most importantly, the detected signals are more accurate for loading controls because proteins on the membrane are not eluted by stripping. We conclude that this direct reprobing method is a simple, inexpensive and accurate method for internal control in Western blotting analysis.
Lipopolysaccharide Affinity Measurement by Scintillation Proximity Assay: Application to Human Heparin Binding Protein
BioTechniques 28:218-222 (February 2000) Bacterial lipopolysaccharide (LPS, endotoxin), the principal lipid component of the outer leaflet of the outer membrane of Gram-negative bacteria, is recognized by defensive cells in essentially all multicellular organisms. Leukocytes respond to LPS by secreting a variety of cytokines. Although the secretory responses to LPS are usually beneficial, an exaggerated response may be fatal. Therefore, great efforts have been put into the development of assays suitable to assess LPS binding to its different targets, e.g., its cellular receptor and a variety of LPS binding proteins in the body.
A number of different cell-binding assays have been developed (4, 7) . The majority of these are designed as separation assays, in which the cells of interest are incubated with labeled LPS and separated by centrifugation from the reaction mixture, after appropriate binding has taken place and following separation and washes. Cell-associated LPS is subsequently detected by means of liquid scintillation counting or fluorescence quantification (radio-and fluorescent probe-labeled ligands, respectively). However, in other situations, it might be of interest not to measure LPS binding to cells but to the purified components of the system. Previously, this has proven to be difficult.
Here, we present a homogeneous LPS binding assay based on scintillation proximity assay (SPA) technology. The purpose of the assay is to measure LPS affinity to any protein of interest.
In our laboratory, we wanted to investigate the LPS binding properties of recombinant human Heparin Binding Protein (hHBP, CAP37, azurocidin). hHBP is a neutrophil glycoprotein (1,2) of importance in host defense during infections and inflammations (5) . To obtain direct binding data, it was necessary to develop an assay that was not based on cells or membrane fragments. To avoid separation procedures and make the assay homogeneous, our choice was to base it on SPA technology.
The SPA technology was invented by Hart and Greenwald in 1978 (3) and further developed and commercialized in 1998 by Amersham Pharmacia Biotech (Piscataway, NJ, USA). The technology is based on the use of radiolabeled lig -ands, which, through the release of βparticles, stimulate a synthetic bead (the SPA bead), thereby producing scintillation. The radiolabeled ligand is only able to generate scintillation when it is in close proximity to the SPA bead (within 1.5 µ m for 3 H-labeled ligands). If the ligand is farther away, a substantial part of the energy in the emitted radiation will be absorbed by the aqueous media. In this particular SPA, hHBP is bound to the SPA bead and mixed with the radiolabeled LPS ( 3 H-LPS). Therefore, 3 H-LPS bound to hHBP on the bead will give a strong signal, while free 3 H-LPS in solution only generates a faint background signal.
The LPS binding assay was carried out in opaque 96-well microplates (Op -tiPlate ® ; Packard Instruments, Meriden, CT, USA). The buffer used contained 20 mM phosphate, pH 7.4, 150 mM NaCl, 1.0 mM EDTA to decrease LPS aggregation and 0.05% BSA. All reagents were from Sigma (St. Louis, MO, USA) except where noted. To each well, we added 0.1 mg poly(vinyltoluene) SPA beads conjugated with Protein A (Amersham Pharmacia Biotech), rabbit anti-hHBP antiserum raised at Novo Nordisk A/S (diluted 1:4000), 0.10 µ g/mL recombinant hHBP, produced at Novo Nordisk A/S as described (6), and increasing concentrations of 3 H-LPS ( Escherichia coli K12 LCD 25, specific activity 2.1 × 10 6 dpm/ µ g (List Biological Laboratories, Campbell, CA, USA), from 0 − 910 ng/mL. To verify that the generated signal was due to specific binding of 3 H-LPS, control wells were produced in which either hHBP or antiserum was omitted. Nonspecific binding was measured in parallel by the addition of 20 µ g/mL unlabeled LPS ( E. coliK12, List Biological Laboratories). The final volume in each well was 200 µ L, and all samples were repeated in triplicate.
After the addition of all reagents, the microplate was sealed with clear adhesive foil. To obtain equilibrium, the samples were incubated at 25°C for 2 h. Following the incubation, the SPA beads were collected at the bottom of the microplate by centrifugation at 1500 ×gfor 2 min. The plate was counted in a microplate scintillation counter (TopCount ® , Packard Instruments). The obtained SPA cpm values were converted into nanogram bound 3 H-LPS: First, the SPA cpm values were multiplied by the conversion factor (determined in a separate experiment as recommended by Amersham Pharmacia Biotech) from SPA cpm into dpm. Second, the generated DPM were divided with the specific activity of the 3 ed by subtracting the nonspecific binding from the total binding. To determine the degree of ligand depletion, aliquots were withdrawn from the supernatant in each well and counted by liquid scintillation. The experimental set-up is depicted in Figure 1 . hHBP binds 3 H-LPS in a saturable manner (Figure 2 ). By using scientific software, curvefits to the data were performed. The apparent K d was determined to be 90 ± 5 ng/mL and the B max to 0.2 ng 3 H-LPS/ng hHBP. The nonspecific binding increases by adding to the 3 H-LPS concentration in a direct proportional manner, as expected. In the absence of either hHBP or anti-hHBP antiserum, only negligible signals are produced (results not shown), which verifies that the observed signal is highly dependent on both hHBP and anti-hHBP antiserum. The ligand depletion was 40% at 25 ng/mL and 10% at 912 ng/mL. In our laboratory, this assay has been used for competitive studies. The experiments showed that LPS from different species were able to compete with 3 H-LPS binding to hHBP (results not shown).
The results presented demonstrate that the assay is a powerful method for measuring LPS affinity of different proteins. Furthermore, whole cells or fragments can be incorporated instead of the purified hHBP. Most interestingly, the assay can be used in screening programs for enhancers and inhibitors of LPS binding.
Suitability of a Unique 16S rRNA Gene PCR Product as an Indicator of Gardnerella vaginalis
BioTechniques 28: 222-226 (February 2000) To find a unique DNA fragment that would be indicative of the bacterium Gardnerella vaginalis , an indicator strain of a common disorder in women, that is known as bacterial vaginosis, we initiated studies on a 16S rRNA variable region (V)-based PCR method that was originally proposed by Barry et al. (1) . In all the studies that we carried out previously on G. vaginalis genomic DNA markers, DNA polymorphism appeared to be the norm in this organism (5, 6, 8) .
We amplified a conserved sequence that spanned the two variable regions, V2 and V6, in G. vaginalis 16S rRNA gene. We used the 20-base G. vaginalis sequence-specific primers that were based on the available DNA sequence data for G. vaginalis ATCC 14018 type strain (GenBank ® Accession No. M58744; D. Yang and C.R. Woose, unpublished observation). The two primers spanning the 5 ′ end of the V2 region (V2-R1, nucleotide 5-24) and the 3 ′ end of the V6 region (V6-U2, nucleotide 1026-1045) differed from the universal primers (1) by 8 bases for V2-R1 and 7 bases for V6-U2 (Table 1) .
A reaction volume of 50 µ L contained: 50 ng G. vaginalis DNA, isolated by a procedure described previously (7) ; 25 pmol each of V2-R1 and V6-U2 primers (synthesized by Operon, Alameda, CA, USA); 100 mM Tris-HCl, pH 8.3, 500 mM KCl; 1.5 mM MgCl 2 (all three from PE Biosystems, Foster City, CA, USA); 200 µ M each of the four dNTPs (New England Biolabs, Beverly, MA, USA); and 1 unit of Taq DNA polymerase (Sigma, St. Louis, MO, USA). PCR was carried out in a Model 480 Thermal Cycler (PE Biosystems) with an initial denaturation at 94°C for 5 min followed by 25 cycles of 1 min denaturation at 94°C, 2 min annealing at 62°C, 3 min extension at 72°C and ending with a final extension step of 10 min at 72°C.
A single G. vaginalisDNA PCR product (V2/V6-sequence) of about 1 kb was observed in agarose gel electrophoresis ( Figure 1 ). This product correlated to the expected 1041 bp in the available DNA sequence data for ATCC 14018 type strain and was confirmed independently by sequencing the V2/V6 product itself. The exact same PCR profile was observed in all 50 G. vaginalis isolates tested (plus ATCC 14018 and ATCC 14019 strains). As a control, DNA from 14 other bacteria listed in Table 1 gave no products, although the DNA sequence from some of these bacteria show more than 50% homology with the primers (deduced from available data in GenBank; see Table I ). This finding indicates the stringency of the PCR conditions for the G. vaginalis V2/V6 DNA sequence. As a further control, human placental DNA (Type
